Madhu Suryadevara, MD
Infectious Disease · Newark, NJNPI 1578906772
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 73.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $16,877 and has fallen 94.3% since, to $962 in 2025. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $90.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$18K
- La Jolla Pharmaceutical Company$2K
- Viiv Healthcare Company$2K
- Theratechnologies Inc.$640
- Merck$324
- Shionogi Inc$297
- plus $752 from 11 others
What the payments were for
- Consulting fees$4372%
- Speaking & faculty fees$14,06059%
- Travel & lodging$2,74011%
- Food & beverage$6,62928%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 83 | $17,613 |
| La Jolla Pharmaceutical Company | 10 | $2,416 |
| Viiv Healthcare Company | 85 | $1,837 |
| Theratechnologies Inc. | 18 | $640 |
| Merck | 19 | $324 |
| Shionogi Inc | 5 | $297 |
| Melinta Therapeutics, LLC | 11 | $215 |
| Johnson & Johnson(2 entities) | 10 | $169 |
| AbbVie | 6 | $87 |
| Napo Pharmaceuticals Inc | 5 | $86 |
| Astellas Pharma US Inc | 3 | $58 |
| Dynavax Technologies Corporation | 4 | $50 |
| Pfizer | 1 | $23 |
| Angiodynamics, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,877 in reported general payments places this provider in the 90th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 390 | $1,631,140 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 80 | $430,691 |
| JulucaDolutegravir/Rilpivirine | 97 | $358,879 |
| CabenuvaCabotegravir/Rilpivirine | 35 | $252,724 |
| Amphotericin B Liposome | 32 | $224,103 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 52 | $195,459 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 50 | $191,254 |
| DovatoDolutegravir Sodium/Lamivudine | 43 | $149,539 |
| TivicayDolutegravir Sodium | 62 | $145,321 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $52,992 |
| PifeltroDoravirine | 25 | $42,673 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $32,682 |
| MicafunginMicafungin Sodium | 32 | $8,535 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 14 | $705 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $17,613 | $1,716,814417 claims |
| Viiv Healthcare CompanyJuluca, Cabenuva, Triumeq, Dovato, Tivicay | $1,837 | $1,101,922289 claims |
| MerckPifeltro | $324 | $42,67325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Newark
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Shobha SwaminathanNewark$60K
- Sally HodderNewark$47K
- Wanda FigueroaNewark$14K
- Alexander StolerNewark$6K
- Hamid ShaabanNewark$5K
- Keith GottesdienerRahway$2.1M
- Ronald NahassHillsborough$213K
- Christopher LucastiSomers Point$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.